What Are Wall Street Analysts' Target Price for West Pharmaceutical Services Stock?

Core Insights - West Pharmaceutical Services, Inc. (WST) has a market capitalization of $18.6 billion and operates globally in the design, manufacture, and sale of containment and delivery systems for injectable drugs and healthcare products [1] Performance Overview - WST stock has significantly underperformed the broader market, with a decline of 17.3% over the past 52 weeks and 21.3% year-to-date, while the S&P 500 Index has gained 10.5% over the past year and 11.2% in 2025 [2] - The company has also lagged behind the Healthcare Select Sector SPDR Fund (XLV), which saw a 6% increase over the past 52 weeks and 10.1% gains in 2025 [3] Recent Financial Results - Following the release of better-than-expected Q3 results on October 23, WST's stock surged 10.9% in a single trading session [4] - For Q3, net sales increased by 7.7% year-over-year to $804.6 million, exceeding expectations by 2.4% [4] - Adjusted EPS rose by 5.9% year-over-year to $1.96, surpassing consensus estimates by 17.4% [4] Future Projections - Analysts project an adjusted EPS of $7.07 for the full fiscal year 2025, reflecting a 4.7% year-over-year increase [5] - WST has a strong earnings surprise history, having exceeded bottom-line estimates in each of the past four quarters [5] Analyst Ratings - Among 15 analysts covering WST, the consensus rating is a "Strong Buy," consisting of 11 "Strong Buys," one "Moderate Buy," and three "Holds" [5] - A month ago, the sentiment was slightly less optimistic, with 10 analysts recommending "Strong Buy" [6] Price Target Insights - TD Cowen analyst Brendan Smith initiated coverage of WST with a "Buy" rating and set a price target of $350, indicating a 35.8% premium to current price levels [7] - The highest price target from analysts is $390, suggesting a potential upside of 51.3% [7]